Literature DB >> 3294577

Effect of cytokines on specific in vitro immunization of human peripheral B lymphocytes against T-cell dependent antigens.

L Danielsson, S A Möller, C A Borrebaeck.   

Abstract

The requirements for a primary, antigen-specific in vitro immunization of human peripheral lymphocytes using haemocyanin, a T-cell dependent antigen, have been studied. In order to obtain a specific response in vitro the peripheral lymphocytes had to be separated into B, T, accessory (A) and dendritic (D) cells. These cells were activated and reconstituted to give a population with a B:T ratio of 1:2. If the induction was supported by MHC-restricted, radioresistant T cells, this cell population could then be antigen-specifically activated using haemocyanin. The immunization had also to be supported by cytokines, such as B-cell growth and differentiation factors, interleukin-2 and gamma-interferon. A 5-day in vitro immunization using 2 micrograms haemocyanin/ml resulted in 200-300 cells secreting anti-haemocyanin-specific antibodies per 10(6) B cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3294577      PMCID: PMC1453298     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  23 in total

1.  The production of a soluble human T-lymphocyte derived factor which substitutes for helper T lymphocytes in the in vitro production of immunoglobulin.

Authors:  R H Stevens; C J Thiele; A Saxon
Journal:  Immunology       Date:  1979-03       Impact factor: 7.397

2.  In vitro immunization as an adjunct to the production of hybridomas producing antibodies against the lymphokine osteoclast activating factor.

Authors:  R A Luben; M A Mohler
Journal:  Mol Immunol       Date:  1980-05       Impact factor: 4.407

3.  In vitro immunization for the production of antigen-specific lymphocyte hybridomas.

Authors:  C A Borrebaeck
Journal:  Scand J Immunol       Date:  1983-07       Impact factor: 3.487

4.  Antibody producing human-human hybridomas. I. Technical aspects.

Authors:  L Olsson; H Kronstrøm; A Cambon-De Mouzon; C Honsik; T Brodin; B Jakobsen
Journal:  J Immunol Methods       Date:  1983-06-24       Impact factor: 2.303

5.  Histocompatibility requirements for T cell help in specific in vitro antibody responses to influenza virus by human blood lymphocytes.

Authors:  R E Callard; C M Smith
Journal:  Eur J Immunol       Date:  1981-03       Impact factor: 5.532

6.  Use of gelatin/plasma coated flasks for isolating human peripheral blood monocytes.

Authors:  B Freundlich; N Avdalovic
Journal:  J Immunol Methods       Date:  1983-08-12       Impact factor: 2.303

7.  Antigen-specific human T cell factors. I. T cell helper factor: biololgic properties.

Authors:  C J Heijnen; F Uytdehaag; K H Pot; R E Ballieux
Journal:  J Immunol       Date:  1981-02       Impact factor: 5.422

8.  T-T interactions in the induction of antigen-specific human suppressor T lymphocytes in vitro.

Authors:  F Uytdehaag; C J Heijnen; K H Pot; R E Ballieux
Journal:  J Immunol       Date:  1979-08       Impact factor: 5.422

9.  Expression and characterization of the product of a human immune interferon cDNA gene in Chinese hamster ovary cells.

Authors:  S J Scahill; R Devos; J Van der Heyden; W Fiers
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

10.  Ia expression by vascular endothelium is inducible by activated T cells and by human gamma interferon.

Authors:  J S Pober; M A Gimbrone; R S Cotran; C S Reiss; S J Burakoff; W Fiers; K A Ault
Journal:  J Exp Med       Date:  1983-04-01       Impact factor: 14.307

View more
  2 in total

1.  The human repertoire of antibody specificities against Thomsen-Friedenreich and Tn-carcinoma-associated antigens as defined by human monoclonal antibodies.

Authors:  B Jansson; C A Borrebaeck
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Human monoclonal antibodies produced by primary in vitro immunization of peripheral blood lymphocytes.

Authors:  C A Borrebaeck; L Danielsson; S A Möller
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.